Allergan ruling casts doubt on tribal patent strategy

(Reuters) - A U.S. judge ’s ruling on Monday invalidating Allergan Plc's patents on its blockbuster $1.5 billion dry-eye medicine, Restasis, has cast doubt on the company's novel strategy to enlist a Native American tribe to help shield those patents from challenge by generic drugmakers, legal experts said.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news